48.1 F
New York
Monday, November 30, 2020

Why Aptevo Therapeutics [NASDAQ: APVO] Skyrocketing Today?

Must read

Tesla [NASDAQ: TSLA] Recalls 9537 SUV’s Because Of Manufacturing Issues

Tesla Inc. has released safety recall orders for more than 9500 of its vehicle in the United States. The vehicles include Model Xs...

Northrop [NYSE:NOC] awarded a deal of $4.8B for Global Hawk Aircraft

Northrop Gruman Corp. has been awarded a deal to perform development, transformation, retrofit, and sustenance activities for the Global Hawk Program. This deal...

Athene Enters Into An Agreement With Hertz To Buy Donlen Corp.

Athene Holdings ltd. entered into a deal to buy Donlen corporation from Hertz Global Holdings Inc. Hertz's fully own Donlen Corporation. The stock...

Verizon [NYSE: VZ] Announced to acquire Tracfone for $6.25 billion.

Verizon Communication Inc. declared that it penned down a deal with America Movil to purchase Tracfone for $6.25B. The companies came to terms...

Aptevo Therapeutics Inc. [NASDAQ: APVO] kicked off the Monday session with a strong performance as its shares soared 89.87%. The strong performance of the company showed the positive sentiments of investors after it has shared an update on its ongoing APVO436 clinical trial.

A biotechnology company has reported that it has observed second complete remission in a Patient in cohort 6. Earlier, on November 6 the company has received the data regarding cohort 6. It has witnessed complete remission in the second patient.

Additionally, there are two patients who have showed the postive signs in cohort 6 of the clinical trial.

Shares of Aptevo Therapeutics Inc. [NASDAQ: APVO] went up 89.87% at $45.00 at the time of writing on Monday. It had recorded a trading volume of 3.01 million as compared to the average volume of 1.43 million.

Looking at its profitability, it has a return on assets (ROA) of -48.20% and returns on equity (ROE) of -137.20%. Focusing on its liquidity, it has a current ratio of 1.50. Furthermore, APVO has total market capitalization of $68.49 million at the time of writing.

A total of nine patients are enrolled in cohort 6 of the clinical trial. One patient has shown the stable disease status and 6 patients have experienced the progress in disease.

Furthermore, President and CEO of Aptevo Therapeutics, Marvin White, said that this is the greatest achievement of the company as two patients have shown the complete disappearacne of the disease. CEO revealed that the company has now started the enrollment for chort 8.

APVO436 is the bispecific antibody therapy that is manufactured on the next-generation proprietary ADAPTIR™ protein therapeutic platform of the Aptevo.

Additionally, this is an investigational therapy that is currently being assessed for the treatment of acute myeloid leukemia (AML).

Biotechnology company has also disclosed that it is scheduled to share two new new posters at the Society for Immunotherapy of Cancer’s (SITC) 35th Virtual Annual Meeting. The meeting to be held on November 9, 2020 to Saturday, November 14, 2020.

More articles

Latest article

ViacomCBS [NASDAQ: VIAC] Agreed To Sell Simon And Schuster For $2.175 Billion In Cash

ViacomCBS Inc. declared that it entered into an agreement with Penguin Random House LCC to sell Simon and Schuster. It will be sold...

IBM [NYSE: IBM] Plans To Cut Down 20% Of Its Workforce

International business machines Corp. declared that the company is preparing to cut down 10,000 jobs in Europe which makes it’s 20% of the...

Ford [NYSE: F ] Booked Ultra-Cold Freezers To Ensure Autoworkers Access To The Covid-19 Vaccine

Ford Motors Co. revealed recently that to stock Pfizer Inc Covid-19 vaccine securely, it has requested 12 of the ultra-cold freezer. The automaker...

Transdigm [NYSE: TDG] Enters Into An Agreement To Buy Cobham Aero Connectivity

Transdigm group incorporation , the global aircraft component manufacturer and provider declared the acquisition of Cobham Aero Connectivity, the top supplier of antennas and...

LCI Industries’ [NYSE: LCII] Subsidiary Lippert Components Acquires Challenger Door

LCI Industries has revealed that its unit Lippert Components has completed the acquisition of Challenger Door, Inc. This acquisition will provide the opportunity...

Blackstone Group [NYSE: BX] Finalizes Recapitalization Of BioMed Realty

The Blackstone Group Inc. has disclosed today that Blackstone Real Estate Partners VIII L.P.  has executed the deal related to BioMed Realty. The...

Pfizer-BioNTech’s COVID19 Vaccine Candidate Acheive 95% Success

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have disclosed Wednesday that their COVID-19 vaccine candidate, BNT162b2, has shown a 95% efficacy rate...

Scienjoy [NASDAQ: SJ] Inks Agreement With China Mobile

Scienjoy Holdings Corporation has revealed today that it has inked a cooperative agreement with China Mobile on November 1, 2020. The company disclosed...